Together, these findings suggest that GCB-type DLBCL patients carrying a MYC rearrangement would probably benefit from treatment strategies other than R-CHOP, for example, more aggressive chemotherapy schemes such as R-DAEPOCH, or the addition of MYC inhibitors. Here, MYC is linked to diffuse large B-cell lymphoma.